The AUCs for the diagnosis of pancreatic cancer (stages I/II/III/IV) using serum EphA2-NF, CA19-9, or EphA2-NF + CA19-9 (vs. test cohort HDs) in the validation cohort were 0.89, 0.89, and 0.97, respectively (Fig. 3E). Here, EPHA2 is linked to familial pancreatic carcinoma.